
New Executive Order Could Thwart Efforts To End HIV
A recent executive order could hinder public health efforts designed to prevent new HIV infections. The EO largely focuses on people experiencing housing insecurities. But it also calls into question the value of harm reduction programs developed to help people who inject drugs. Public health experts argue that such services, like needle exchange programs, are effective. Moreover, these experts fear that the proposed changes could hinder efforts to combat HIV.
The executive order, signed by President Trump on July 24, 2025, states that the secretary of Health and Human Services shall ensure that grants, 'for substance use disorder prevention, treatment, and recovery fund evidence-based programs and do not fund programs that fail to achieve adequate outcomes, including so-called 'harm reduction' or 'safe consumption' efforts that only facilitate illegal drug use and its attendant harm.'
Harm reduction strategies are evidence-based. They do not facilitate illegal drug use. They do save lives.
Harm Reduction Strategies
The idea behind harm reduction is simple. People engage in dangerous activities. Harm reduction strategies minimize the risks. Think about the seatbelts in your car. They reduce car crash fatalities and make driving safer.
Syringe services programs work in the same manner. By ensuring that people who inject drugs have access to clean needles, SSPs make the act of injecting drugs less dangerous. They reduce overdose deaths. They help people get into treatment programs. And they decrease the transmission of HIV.
Injection Drug Use And HIV
The link between injection drug use and HIV transmission was clearly and tragically evident in Indiana over a decade ago. During a one-year period, 181 new HIV infections were confirmed, mostly in Scott County. Almost 90% of those new infections occurred in people who injected drugs. In March 2015, then-governor Mike Pence declared a public health emergency and authorized a short-term needle exchange program to help quell the outbreak. Combined with other public health efforts, this clean needle initiative caused the outbreak to subside. A subsequent modelling study, however, indicated that an earlier response could have prevented even more infections.
The events that occurred in Scott County, Indiana easily could occur elsewhere. Indeed, researchers have identified 220 counties in the U.S. at risk for HIV or hepatitis C outbreaks among people who inject drugs. A vast majority of the identified counties are rural. Many of them are in Appalachia. Robust harm reduction programs in these areas are needed to help prevent future outbreaks.
Public Health Effects Of Executive Order
When asked about the new executive order, Erin Shoe, public health director at Cabarrus Health Alliance in North Carolina said, 'We know, from firsthand experience, that access to mental health and harm reduction programs and resources save lives. Cabarrus Health Alliance staff are reviewing and interpreting the executive order while we await further guidance from relevant federal agencies. We stand ready to navigate changes to harm reduction programs to ensure those who have needs can access resources in a timely and safe manner.'
According to Dr. Elyse Powell, executive director at North Carolina Harm Reduction Coalition, 'Harm reduction works. It's one of the best tools we have to stop the spread of HIV. People who engage in services are five times more likely to enter treatment and three times more likely to completely stop drug use.'
Erin Major, a PhD candidate in the Health Law, Policy & Management Department at Boston University expressed similar thoughts. 'It's been shown time and time again that harm reduction is effective in terms of reducing not only overdose deaths, but also disease spread. Needle exchange programs can be effective ways to reduce the transmission of HIV. And harm reduction programs can increase treatment engagement,' she said.
These experts also noted the financial benefits of harm reduction strategies. 'This approach isn't just dangerous, it's extremely expensive,' noted Dr. Powell. 'Hepatitis C costs over $25,000 to treat. HIV has lifetime health costs that can total over $420,000. Harm reduction prevents the spread of these illnesses for pennies on the dollar.' Ms. Major agreed, commenting that, 'Preventing an HIV outbreak is much more cost effective than treating people after an outbreak has occurred.'
About 32,000 new HIV infections occurred in the United States in 2022. Approximately 7% of those infections occurred in people who inject drugs. We know that harm reduction strategies like syringe services programs can reduce this number. We also know that these strategies are cost effective. This executive order, however, stands in contrast to the existing evidence. Dr. Powell from NCHRC put it best, commenting that, 'Cutting funding means we'll be fighting this epidemic without one of the best tools in our toolbox.' That shouldn't be acceptable. If we hope to end HIV as a public health emergency in this country, then we need to employ all our resources.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
eHealth (EHTH) Q2 Earnings Report Preview: What To Look For
Online health insurance comparison site eHealth (NASDAQ:EHTH) will be reporting results this Wednesday morning. Here's what to expect. eHealth beat analysts' revenue expectations by 13.4% last quarter, reporting revenues of $113.1 million, up 21.7% year on year. It was an exceptional quarter for the company, with a solid beat of analysts' EBITDA estimates and full-year EBITDA guidance exceeding analysts' expectations. It reported 1.16 million users, down 1.8% year on year. Is eHealth a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting eHealth's revenue to decline 29.5% year on year to $46.41 million, a further deceleration from the 1.4% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$1.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. eHealth has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 13.1% on average. Looking at eHealth's peers in the online marketplace segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Shutterstock delivered year-on-year revenue growth of 21.3%, beating analysts' expectations by 7.5%, and EverQuote reported revenues up 33.7%, in line with consensus estimates. Shutterstock's stock price was unchanged following the results. Read our full analysis of Shutterstock's results here and EverQuote's results here. Investors in the online marketplace segment have had steady hands going into earnings, with share prices up 1.5% on average over the last month. eHealth is down 22.5% during the same time and is heading into earnings with an average analyst price target of $10 (compared to the current share price of $3.21). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
Long Covid Patients Can Sign up for Remote Clinical Trial Notification, Announces CareEvolution
At-home participation in a study by Scripps Research and Schmidt Initiative for Long Covid powered by CareEvolution's MyDataHelps® platform ANN ARBOR, Mich., August 05, 2025--(BUSINESS WIRE)--Long Covid patients around the U.S. looking to participate in a clinical trial from home can sign up to be notified when an upcoming study conducted by scientists at Scripps Research and supported by the Schmidt Initiative for Long Covid (SILC) opens. Patients can sign up on the Long Covid Treatment Trial (LoCITT) website. The upcoming study, powered by the MyDataHelps platform from CareEvolution, is a fully remote clinical trial investigating the efficacy of a repurposed drug for treating Long COVID. It will enroll 1,000 Long Covid patients from across the U.S. The app-based study enables participants to enroll and participate in all trial activities without having to visit a trial clinic. "Decentralized trials broaden reach, speed timelines and yield richer real-world evidence," said Vik Kheterpal, MD, a principal at CareEvolution. "LoCITT will help advance how efficiently we can run trials as we seek treatments for complex, heterogeneous conditions like Long Covid." Long Covid, which has affected the lives of 400 million people worldwide and costs the global economy an estimated $1 trillion per year, can often cause symptoms that make mobility and travel challenging for patients who want to participate in trials. The forthcoming Scripps Research-led trial will rely on the LoCITT platform to enroll patients, distribute drug candidates and placebos, as well as collect and evaluate trial data. "For people with severe Long Covid, travel can be dangerous," said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. "LoCITT enables even patients with the most severe symptoms to join the search for answers." Moore Vogel is co-principal investigator of the study alongside Scripps Research executive vice president Eric Topol. Remote trials, which eliminate the need for patients to report to clinics, enable easier and broader participation. Conducting a Long Covid trial remotely will also allow more representative cohorts—potentially leading to more generalizable findings. "We need aggressive, rapid efforts to turn the tide on this very difficult condition for all the patients who struggle with it," said John Redd, CEO of SILC. "We're hopeful that a remote trial will help us find effective treatments more quickly." CareEvolution adapted its existing MyDataHelps decentralized clinical trial platform specifically for the LoCITT trial, with the potential for it to be used by other research efforts. The platform will allow for patients to be screened, enrolled and randomized more swiftly. Potential treatments and placebos will be mailed directly to the participant's home, along with wearable devices and other technologies to collect patient data. CareEvolution's user-friendly platform allows patients to check their eligibility, provide consent electronically and respond to baseline and ongoing surveys about their symptoms. Patients selected for the study will receive wrist devices to monitor their heart rates, activity and sleep, potentially enabling the development of digital biomarkers for Long Covid and related conditions like myalgic encephalomyelitis (ME), which can cause debilitating fatigue, and postural orthostatic tachycardia syndrome (POTS), which can cause dizziness, fatigue and a rapid heart rate upon standing up. The data from the devices will be uploaded to LoCITT. Prospective participants who are 18 years of age or older and who believe they have Long Covid can sign up at to be notified when the Scripps clinical trial opens. About CareEvolution We Connect Healthcare. MyDataHelps®, our digital clinical trials platform, accelerates healthcare innovation by empowering researchers to configure and launch studies in hours. We enable anyone, anywhere to be able to participate in research using participant centric design that integrates surveys, wearable and sensor data, EHR connectivity, and participant engagement tools to generate robust real-world longitudinal data. Trusted by over 2.5 million participants enrolled in longitudinal initiatives sponsored by health systems, academic institutions, life science companies, foundations, and public health agencies, CareEvolution advances precision health and helps close critical gaps in our collective understanding of complex conditions. For more information please visit About the Schmidt Initiative for Long Covid The Schmidt Initiative for Long Covid (SILC) advances clinical care for Long Covid patients globally. The nonprofit organization, founded in 2023 by philanthropists Eric and Wendy Schmidt, works to raise the level of Long Covid care and understanding around the world, connecting specialists and primary care providers to support patients and share knowledge virtually, in real time. For more information, visit About Scripps Research Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at View source version on Contacts CareEvolutionpr@ Swati Pandey, SILCspandey@ Anna Andersen, Scripps Researchaanders@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
These 5 Surprising Carbs Help You Stay Full and Stick to a Calorie Deficit, Trainer Says
These 5 Surprising Carbs Help You Stay Full and Stick to a Calorie Deficit, Trainer Says originally appeared on Men's Fitness. Carbs are not the root of all evil. But when you're in a calorie deficit, they can feel off-limits. The truth is, carbs are the body's main source of fuel. They power our heavy lifting days, energize outdoor runs, and sustain us through everyday life. Still, some carb-heavy foods like bread can be calorie-dense and feel like a trap when you're trying to cut back. Trainer Dan Go shared five low-calorie carb sources that actually help keep you full while you're in a Carbs Potatoes "Potatoes are low in calories, high in fiber—especially with the skin. This makes them incredibly filling, and also their resistant starch and high water content helps you feel satisfied longer," Go says. Blueberries Blueberries may not be the first food that comes to mind when thinking about carbs. But, with their rich fiber and water content, they're a low-calorie carb that's highly satiating. The fiber in blueberries also slows digestion, which keeps you full and helps stabilize blood sugar. Lentils Lentils are small, but their fiber content is mighty. Along with its carb content, they're also a great source of plant protein, high in satiety. Broccoli "The reason I love broccoli is because it's one of the perfect foods to volumize your meals, because it contains a lot of fiber, a lot of water, and it helps you keep full while giving you an incredible nutrient profile," Go says. Rich in vitamin C, K, and folate, eating broccoli helps support your metabolism and digestion. Apples Go calls apples "nature's appetite suppressant." If you need a sweet treat during your calorie deficit, lean on apples. They're high in fiber and low in calories, helping you curb hunger and reduce snacking. Apples are also rich in 5 Surprising Carbs Help You Stay Full and Stick to a Calorie Deficit, Trainer Says first appeared on Men's Fitness on Jul 10, 2025 This story was originally reported by Men's Fitness on Jul 10, 2025, where it first appeared. Solve the daily Crossword